Group 1B: HER2+ Breast Cancer; Antibody-Drug Conjugates; Targeted Therapies; Clinical Trials; Treatment Resistance

Poster #1105: Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.

Poster #TPS1121: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).

Date

Jun 12 2024

Time

10:00 am - 11:30 am

Zoom Webinar

Category
REGISTER